Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

DDIT4 (DNA-damage-inducible transcript 4)

Written2012-12Silvia Vega-Rubin-de-Celis, James Brugarolas
Departments of Internal Medicine, Developmental Biology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA

(Note : for Links provided by Atlas : click)

Identity

Alias_namesDNA-damage-inducible transcript 4
Alias_symbol (synonym)RTP801
FLJ20500
REDD-1
REDD1
Dig2
Other alias
HGNC (Hugo) DDIT4
LocusID (NCBI) 54541
Atlas_Id 45802
Location 10q22.1  [Link to chromosome band 10q22]
Location_base_pair Starts at 72273919 and ends at 72276036 bp from pter ( according to hg19-Feb_2009)  [Mapping DDIT4.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
AZGP1P1 (7q22.1) / DDIT4 (10q22.1)DDIT4 (10q22.1) / CSNK1D (17q25.3)DDIT4 (10q22.1) / DDIT4 (10q22.1)
H19 (11p15.5) / DDIT4 (10q22.1)NDRG2 (14q11.2) / DDIT4 (10q22.1)NUDCD3 (7p13) / DDIT4 (10q22.1)

DNA/RNA

Description The DDIT4 gene encompasses 2,1 kb, containing 3 exons. Exon 1 includes 142 nucleotides and is non-coding, exon 2 (265 nucleotides) codifies for the first 65 amino acids, and exon 3 (1345 nucleotides) codifies for the remaining 167 amino acids and contains the 3' UTR (NM_019058.2).
Transcription A single mRNA of 1748 nucleotides is expressed from the plus strand and includes a 699 coding sequence, a 201 5' UTR and a 848 3' UTR (ENST00000307365, Ensembl Genome Browser database). Note minor discrepancy in non-coding region (4 nucleotides) between NCBI and Ensembl annotation.

Protein

Note REDD1 is a highly conserved protein of 232 amino acids, with a predicted molecular weight of 25 kDa. Apparent molecular weight on SDS-PAGE is 35 kDa. Amino acid sequence analyses do not show any known structural or functional domains. The crystal structure revealed a new fold and a conserved surface patch that is essential for function (Vega-Rubin-de-Celis et al., 2010).
 
  REDD1 crystal structure (PDB ID: 3LQ9). A) Cartoon diagram of REDD1 (89-226Δ200-204) structure colored in rainbow mode from N- to C- terminus. Dotted line represents a disordered region. B) REDD1 sequence alignment in different species colored in blue gradient according to conservation. Red boxes indicate the sequences forming the conserved functionally important surface patch. C) Conservation mapping of REDD1 surface using the blue gradient color as in (B). Modified with permission from Vega-Rubin-de-Celis et al., Biochemistry, 2010. Copyright (2010) American Chemical Society.
Description REDD1 is conserved from insects to humans, especially in the C-terminal region (Vega-Rubin-de-Celis et al., 2010). The N-terminal 84 amino acids of REDD1 are dispensable for function. The REDD1 crystal structure includes residues 89-226 and has a deletion of a few hydrophobic residues (200-204) that are dispensable for function (Vega-Rubin-de-Celis et al., 2010). The REDD1 protein has two antiparallel α-helices followed by a mixed β-sheet, containing 4 β-strands ordered 2134. Strands β1-β3 make an unusual structural motif known as a psi-loop, two antiparallel strands separated by a third that makes hydrogen bonds with the two flanking strands.
A conserved surface patch that is essential for REDD1 function has been identified. This patch is formed by two regions: a loop between helix α2 and strand β1 (residues 138-141) and residues 218-225, which encompass the C-terminal portion of the strand β4.
REDD1 is an unstable protein, with an estimated half-life of 5-10 min (Kimball et al., 2008; Katiyar et al., 2009). REDD1 has been shown to be phosphorylated at T23 and T25 and phosphorylation at these sites has been postulated to regulate REDD1 half-life. These sites are in an N-terminal region that is dispensable for mTORC1 inhibition (Vega-Rubin-de-Celis et al., 2010). Based on in vitro kinase assays, it was postulated that the kinase implicated in REDD1 phophorylation is Glycogen Sinthase Kinase 3β (GSK3β). HA-GSK3β isolated from transfected HEK293 cells can phosphorylate GST-REDD1 (Katiyar et al., 2009). However, whether GSK3β phosphorylates endogenous REDD1 is still unknown. How these phosphorylation events are implicated in REDD1 stability is also unclear. Katiyar et al. reported a modest increase in REDD1 half-life upon treatment with LiCl, a GSK3β inhibitor, in HEK293 cells. In addition, REDD1 T23A/T25A mutants transfected in HEK293 cells are more stable than wild-type REDD1. However, 35S Methionine/Cysteine pulse-chase experiments in HeLa cells suggested that REDD1 wild-type and the T23A/T25A mutants have a similar half-life and LiCl had no effect on the half-life of endogenous REDD1 in these cells (Vega-Rubin-de-Celis and Brugarolas, unpublished results).
REDD1 half-life has been proposed to be regulated by the CUL4A-DDB1-ROC1-βTRCP-E3 ubiquitin ligase complex (Katiyar et al., 2009). In overexpression experiments in HEK293 cells, Flag-REDD1 was found to interact with the complex components Myc-CUL4A, AU1-DDB1 and HA-βTRCP. In addition, endogenous REDD1 was shown to bind to DDB1 and βTRCP in MCF-7 cells exposed to hypoxia and the proteasome inhibitor MG132 (Katiyar et al., 2009). Furthermore, knock-down of βTRCP by siRNA in MCF-7 cells increased the REDD1 half-life to 25 minutes (Katiyar et al., 2009). Knock-down of other complex components (CUL4A and DDB1) also increased REDD1 half-life, but to a lesser extent (10-15 minutes) (Katiyar et al., 2009).
Several large-scale proteomic studies showed that REDD1 is ubiquitinated at K129 (Meierhofer et al., 2008; Xu et al., 2010; Danielsen et al., 2011; Kim et al., 2011; Lee et al., 2011; Shi et al., 2011; Wagner et al., 2011). Whether this modification affects REDD1 stability (or function) is unknown and K129 is not conserved across species.
Thioredoxin-Interacting protein (TXNIP) has been shown to bind to REDD1 and TXNIP overexpression in HeLa and H1299 cells increased REDD1 levels (Jin et al., 2011). However, these experiments were performed with ectopically expressed protein and whether the endogenous proteins interact and whether TXNIP regulates REDD1 stability remains to be determined.
A yeast-two hybrid screen of a human leukocyte library reported several putative binding proteins (Gery et al., 2007), and other studies identified other REDD1 interacting proteins including TXNIP (DeYoung et al., 2008; Jin et al., 2011). However, none have been validated with endogenous REDD1 protein.
Expression REDD1 is developmentally regulated. Redd1 expression has a similar pattern as p63, being expressed at early stages in the apical ectodermal ridge and later on, at ectoderm-derived tissues (Ellisen et al., 2002). Interestingly, p63-/- embryos have lower Redd1 levels suggesting that p63 is an important developmental regulator of REDD1 (Ellisen et al., 2002).
REDD1 mRNA is broadly induced in response to hypoxia (Shoshani et al., 2002; Wolff et al., 2011). Using mice with a gene trap reporter (β-geo) inserted in Redd1 intron 2, Wolff et al. showed that Redd1 is induced after 1h of hypoxia in most of the tissues analyzed, with the exception of cardiac and skeletal muscle. Redd1 was broadly induced in endothelial cells as well as in cells in the crypts of the small bowel, bronchial epithelial cells, cells in zone 3 in the liver, cells lining the collecting ducts of the kidney, red pulp and histiocytes in the spleen and Purkinje cells in the cerebellum (Wolff et al., 2011).
REDD1 is a hypoxia inducible factor (HIF) target (Shoshani et al., 2002). HIF-1 and -2 are heterodimeric transcription factors containing an α-subunit that is regulated by oxygen levels through hydroxylation (Ivan et al., 2001; Jaakkola et al., 2001; Masson et al., 2001; Yu et al., 2001) and a β-subunit (also called aryl hydrocarbon receptor nuclear translocator, ARNT) that is stable (Semenza, 2006). Hydroxylated HIFα is recognized by an ubiquitin ligase complex containing the von Hippel-Lindau (pVHL) tumor suppressor protein (Cockman et al., 2000; Kamura et al., 2000; Ohh et al., 2000; Tanimoto et al., 2000). It has been shown in cell lines and mouse models that REDD1 induction is VHL and HIF-dependent (Kucejova et al., 2011). REDD1 is a target of both HIF1α and HIF2α, as assessed by ChIP assays and siRNA experiments in clear cell renal cell carcinoma (ccRCC) cell lines 786-O, A498 and Caki-2 (Kucejova et al., 2011).
MEFs deficient for ataxia telangiectasia mutated (ATM) are unable to induce HIF1α (and REDD1) in response to hypoxia suggesting that, at least in some contexts, ATM may be required for HIFα stabilization (Cam et al., 2010).
Besides hypoxia, REDD1 is also induced in response to a variety of other stress conditions, including ER stress (Wang et al., 2003; Whitney et al., 2009), osmotic stress (Wang et al., 2003) and in response to DNA-damaging agents (Ellisen et al., 2002; Lin et al., 2005a). Other REDD1 inducers include glucocorticoids (Wang et al., 2003; Boldizsar et al., 2006) and all-trans-retinoic acid (ATRA) (Gery et al., 2007).

Apart from HIF1 and 2, other transcription factors have been implicated in REDD1 induction:
- ATF4 (activating transcription factor 4): REDD1 is induced under ER stress conditions in an ATF4-dependent manner (Whitney et al., 2009). Experiments performed in HepG2 cells showed REDD1 induction with the ER stress inducers Thapsigargin and Tunicamycin. This induction was shown to be protein kinase RNA-like ER kinase (PERK) and ATF4-dependent based on studies on PERK or ATF4-deficient MEFs. In addition, ectopically overexpressed ATF4 was sufficient to induce REDD1 expression in HEK293.
- CREBP (CCAAT/enhancer-binding protein): DNA-damaging agent MMS induces REDD1 mRNA in HaCaT cells in a CREBP-dependent manner (Lin et al., 2005a). Luciferase reporter assays identified a MMS-responsive region within -1057/-981 (Lin et al., 2005a) which included a putative CREBP site at -1009/-999, and CREBP was found to bind to this sequence in EMSA.
- Elk1: REDD1 mRNA is induced in HaCaT cells exposed to arsenite, in a Elk1 and CCAAT/enhancer-binding protein (CREBP)-dependent manner (Lin et al., 2005b). Luciferase reporter assays in HaCaT cells mapped the arsenite-responsive region to the -1057/-981 (Lin et al., 2005b), and EMSA assays showed CREBP binding to that region.
- NFATc3 (nuclear factor of activated T-cell): in intestinal cells REDD1 is induced by the NFAT activators PMA and A23187, and siRNA knockdown of NFATc3 but not other family members compromised PMA/A23187-induced REDD1 expression (Zhou et al., 2012). Luciferase-reporter assays showed that NFATc3 was sufficient to activate expression of REDD1 promoter sequences and ChIP assays in HT29 cells showed binding of NFATc3 (-2931/-97) (Zhou et al., 2012).
- p53: MEFs treated with ionizing radiation induced REDD1 in a p53-dependent manner, and overexpression of p53 in SAOS and U2OS cells induced REDD1 (Ellisen et al., 2002). Luciferase reporter assays in U2OS cells identified a p53-responsive element at -600 bp (Ellisen et al., 2002).
- Sp1: REDD1 levels are increased in high cell densities in a Sp-1 dependent manner (Jin et al., 2007). Sp1 siRNA in HeLa cells abolished REDD1 induction by high cell density. Sp1 can also contribute to REDD1 induction in hypoxia or in response to hypoxia mymetics (Jin et al., 2007), and siRNA experiments compromised CoCl2-dependent REDD1 induction. The putative Sp1 binding site was mapped to -476/-446 of the REDD1 promoter by luciferase-reporter assays in HeLa cells (Jin et al., 2007).

The REDD1 promoter region contains putative target sequences for other transcription factors, including NFkB and hepatocyte-nuclear factor 4 (HNF4) (Lin et al., 2005b).

Localisation REDD1 has been reported to be localized in both nuclear and cytosolic compartments in overexpression experiments (Ellisen et al., 2002; Lin et al., 2005b). Biochemical fractionation studies of the endogenous protein did not show REDD1 in the nucleus, but indicated that REDD1 is both in a cytosolic and a membrane compartment (DeYoung et al., 2008). In Redd1-/- MEFs transduced with a retroviral vector encoding for REDD1, REDD1 localized to the mitochondria (Horak et al., 2010). Further studies are required with the endogenous protein. However, preliminary experiments (both in normoxia and hypoxia conditions) suggest that REDD1 is in the cytosol and that it is peripherally associated with a membrane compartment (Vega-Rubin-de-Celis et al., unpublished results).
Function REDD1 is induced in hypoxia and is both necessary and sufficient for hypoxia-induced mammalian target of rapamycin complex 1 (mTORC1) inhibition (Brugarolas et al., 2004). MEFs deficient for Redd1 (Brugarolas et al., 2004; DeYoung et al., 2008; Wolff et al., 2011) fail to inhibit mTORC1 in response to hypoxia, and depletion experiments with siRNAs or shRNA in HeLa, HEK293 and U937 cells compromised hypoxia-induced mTORC1 inhibition (Corradetti et al., 2005; Gery et al., 2007; Vega-Rubin-de-Celis et al., 2010). Overexpression of REDD1 in multiple cell types including U2OS (Brugarolas et al., 2004; Sofer et al., 2005; DeYoung et al., 2008; Vega-Rubin-de-Celis et al., 2010), HeLa (Vega-Rubin-de-Celis et al., 2010), MEFs (Sofer et al., 2005), and HEK293 (Corradetti et al., 2005) cells is sufficient for mTORC1 inhibition.
REDD1 has a paralogue, REDD2 (DDIT4-like (DDIT4-L) or RTP801-like (RTP801-L)). REDD1 and REDD2 appear to be have originated from a gene duplication event that occurred independently in humans and insects (Vega-Rubin-de-Celis et al., 2010). However, unlike Redd1, Redd2 is not induced by hypoxia, at least in MEFs (Wolff et al., 2011). Nevertheless, like REDD1, REDD2 overexpression is sufficient to inhibit mTORC1 (Brugarolas et al., 2004).
The Drosophila orthologues, scylla and charybdis, were identified in a screen to isolate inhibitors of an increased cell size phenotype generated by simultaneously expressing PDK1 and Akt (Reiling and Hafen, 2004). Both genes contain consensus hypoxia-response elements (HRE) sequences (Reiling and Hafen, 2004). Scylla expression is also induced in response to hypoxia in the larval fat body and the gut. Charybdis mRNA was not induced in the fat body and only slightly in the midgut (Reiling and Hafen, 2004). In addition, charybdis is not induced through overexpression of constitutively active Drosophila HIFα (sima) or Hifβ (tgo) (Reiling and Hafen, 2004).
Even though REDD1 induction broadly inhibits mTORC1, under some conditions (and for reasons that are not understood), this is not the case in ccRCC. VHL is inactivated in a majority of ccRCC cases, leading to stabilization of HIF1/HIF2 and increased REDD1 levels. However, REDD1 does not appear to inhibit mTORC1, and mTORC1 is frequently activated in ccRCC (Kucejova et al., 2011).
Hypoxia-induced mTORC1 inhibition is dependent on the tuberous sclerosis complex 1 and 2 proteins, which form a complex (TSC1/TSC2). This has been shown in a variety of systems. Tsc2-/- MEFs fail to inhibit mTORC1 when exposed to hypoxia or to ectopic Redd1, but they regain their ability to inhibit the pathway after Tsc2 reconstitution (Brugarolas et al., 2004; Corradetti et al., 2005; Sofer et al., 2005). Depletion of TSC2 with siRNA in U2OS, HeLa, HEK293 and MCF10A cells also compromises mTORC1 inhibition by hypoxia or REDD1 overexpression (Brugarolas et al., 2004; Connolly et al., 2006; Vega-Rubin-de-Celis et al., 2010).
However, hypoxia-induced mTORC1 inhibition can also occur independently of mTORC1. In hepatocytes, mTORC1 inhibition by hypoxia is REDD1-independent. In this cell type, hypoxia signals are transduced in a manner that is also independent of Tsc1/Tsc2 and Hif (Wolff et al., 2011).
It was suggested that REDD1 acts by sequestering 14-3-3 proteins from TSC2 thereby activating TSC2 and inhibiting mTORC1 (DeYoung et al., 2008). However, how REDD1 would selectively sequester TSC2-bound 14-3-3 versus the whole 14-3-3 pool in the cell, which is quite large, is not clear. Furthermore, the putative 14-3-3 binding site in REDD1 does not conform to any of 14-3-3 binding sites known (Vega-Rubin-de-Celis et al., 2010), and endogenous REDD1 does not seemingly bind to 14-3-3 proteins. Moreover, the postulated 14-3-3 binding motif in REDD1 (133RLAYSEP139) is not conserved, and mutations of R133 and S137 that might have expected to be critical for 14-3-3 binding do not abrogate REDD1 function (Vega-Rubin-de-Celis et al., 2010).
REDD1 is developmentally regulated in both flies and in mice, but Redd1 is dispensable for development in mice (Brafman et al., 2004; Yoshida et al., 2010; Molitoris et al., 2011; Wolff et al., 2011). In addition, loss of both scylla and charybdis does not cause lethality in flies. However, their loss severely compromised larval survival in hypoxia conditions (Reiling and Hafen, 2004). Interestingly, disruption of Redd1 in mice does not result in a compensatory induction by the paralogue Redd2, which has been shown to also inhibit mTORC1 in overexpression experiments in HeLa cells (Brugarolas et al., 2004).

Mutations

Note A frameshift inactivating mutation (c.550delC) was found in ccRCC (Kucejova et al., 2011). However, no other REDD1 mutations where identified in sequencing analyses of 77 tumors.
Somatic A somatically acquired mutation was identified in a pancreatic tumor (c.571G>T; p.G191W) (Sanger Institute, COSMIC database). While the residue is not conserved, according to PolyPhen-2, the mutation is probably damaging, but whether it affects function is unclear.
A mutation in prostate cancer (c.253A>C; p.S85R) has been described (Sanger Institute, COSMIC database). It is unknown whether the mutation was somatically acquired and according to PolyPhen-2 it is probably damaging. An additional somatically acquired mutation was found in prostate carcinoma (c.253A>C); however, it is a synonymous substitution (p.L96L) (Sanger Institute, COSMIC database).
Two mutations have been detected in lung squamous cell carcinoma (G75R and A37V) (Hammerman et al., 2012, cBIO Cancer Genomics). They are both somatically acquired (Sanger Institute, COSMIC database), and according to PolyPhen-2 they are predicted to be benign.
Two mutations have been identified in uterine corpus endometrioid carcinoma (H91R and R143W) (cBIO Cancer Genomics). They are somatically acquired, (Sanger Institute, COSMIC database) and according to PolyPhen-2 they are predicted to be benign (H91R) or probably damaging (R143W).
A somatically acquired mutation was identified in two samples of lung carcinoma (c.4C>T; p.P2S) (Sanger Institute, COSMIC database). Pro2 residue is in a dispensable region in REDD1; however, according to Polyphen2 is probably damaging.
A synonymous somatically acquired substitution mutation was also described in lung carcinoma (c.561C>G; p.P187P) (Sanger Institute, COSMIC database).
A somatically acquired mutation was identified in cervix carcinoma (c.79G>C; p.D27H) (Sanger Institute, COSMIC database). It is in a dispensable region in REDD1 and predicted to be benign based on Polyphen2.
In urinary tract carcinoma samples a somatically acquired mutation was found (c.671C>T; p.S224L) (Sanger Institute, COSMIC database). It is predicted to be probably damaging by Polyphen2.

Implicated in

Note
  
Entity Cancer
Note DDIT4 has been shown to be mutated in a handful of cancers at low frequency. However, mutations may not be detrimental and while it would be fitting for a negative mTORC1 regulator to act as a tumor suppressor, whether this is the case remains to be determined and no tumor predisposition has been reported in Ddit4-deficient mice. Interestingly, REDD1 is over expressed in most of the ccRCC tumors, due to the loss of pVHL and HIF1/HIF2 stabilization. Paradoxically this increase does not lead to mTORC1 inhibition, and mTORC1 is usually activated in ccRCC (Kucejova et al., 2011).
  
  
Entity Viral infection
Note REDD1 has been recently implicated as a host defense factor in response to viral infections. In Redd1-/- MEFs, there is increased viral protein translation after viral infection in a mTORC1 dependent manner (Mata et al., 2011). Treatment with Rapamycin downregulated viral proteins in both Redd1+/+ and Redd1-/- MEFs, suggesting that the mTORC1 is implicated in viral protein synthesis. Naphthalimides (which inhibit NS1, an influenza A virus virulence factor) induce REDD1 and inhibit mTORC1 thereby reducing viral protein production. REDD1 may be essential for their antiviral effect, as the antiviral effect was abolished in Redd1-/- cells. Similarly, in Tsc2-/- cells naphthalimides failed to downregulate viral protein expression.
  
  
Entity Parkinson disease
Note Redd1 was found to be increased in cellular and animal models of Parkinson disease (Malagelada et al., 2006; Malagelada et al., 2008). It has been shown to increase neuronal cell death through a mechanism involving mTORC1 and Akt. In PC12 cells treatment with 6OHDA induces Redd1 and increases cell death; this phenotype is rescued by knock-down of Redd1. Furthermore, Redd1 overexpression is sufficient to induce cell death.
  

Bibliography

Low glucocorticoid receptor (GR), high Dig2 and low Bcl-2 expression in double positive thymocytes of BALB/c mice indicates their endogenous glucocorticoid hormone exposure.
Boldizsar F, Palinkas L, Czompoly T, Bartis D, Nemeth P, Berki T.
Immunobiology. 2006;211(10):785-96. Epub 2006 Jul 28.
PMID 17113916
 
Inhibition of oxygen-induced retinopathy in RTP801-deficient mice.
Brafman A, Mett I, Shafir M, Gottlieb H, Damari G, Gozlan-Kelner S, Vishnevskia-Dai V, Skaliter R, Einat P, Faerman A, Feinstein E, Shoshani T.
Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3796-805.
PMID 15452091
 
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr.
Genes Dev. 2004 Dec 1;18(23):2893-904. Epub 2004 Nov 15.
PMID 15545625
 
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1a.
Cam H, Easton JB, High A, Houghton PJ.
Mol Cell. 2010 Nov 24;40(4):509-20. doi: 10.1016/j.molcel.2010.10.030.
PMID 21095582
 
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.
J Biol Chem. 2000 Aug 18;275(33):25733-41.
PMID 10823831
 
Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells.
Connolly E, Braunstein S, Formenti S, Schneider RJ.
Mol Cell Biol. 2006 May;26(10):3955-65.
PMID 16648488
 
The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway.
Corradetti MN, Inoki K, Guan KL.
J Biol Chem. 2005 Mar 18;280(11):9769-72. Epub 2005 Jan 4.
PMID 15632201
 
Mass spectrometric analysis of lysine ubiquitylation reveals promiscuity at site level.
Danielsen JM, Sylvestersen KB, Bekker-Jensen S, Szklarczyk D, Poulsen JW, Horn H, Jensen LJ, Mailand N, Nielsen ML.
Mol Cell Proteomics. 2011 Mar;10(3):M110.003590. doi: 10.1074/mcp.M110.003590. Epub 2010 Dec 7.
PMID 21139048
 
Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.
DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW.
Genes Dev. 2008 Jan 15;22(2):239-51. doi: 10.1101/gad.1617608.
PMID 18198340
 
REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.
Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DA.
Mol Cell. 2002 Nov;10(5):995-1005.
PMID 12453409
 
RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation.
Gery S, Park DJ, Vuong PT, Virk RK, Muller CI, Hofmann WK, Koeffler HP.
Exp Hematol. 2007 Apr;35(4):572-8.
PMID 17379067
 
Comprehensive genomic characterization of squamous cell lung cancers.
Hammerman PS, Lawrence MS, Voet D, Jing R, Cibulskis K, Sivachenko A, Stojanov P, McKenna A, Lander ES, Gabriel S, Getz G, Sougnez C, Imielinski M, Helman E, Hernandez B, Pho NH, Meyerson M, Chu A, Chun HJ, Mungall AJ, Pleasance E, Robertson A, Sipahimalani P, Stoll D, Balasundaram M, Birol I, Butterfield YS, Chuah E, Coope RJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Lee D, Li HI, Mayo M, Moore RA, Mungall K, Nip KM, Olshen A, Schein JE, Slobodan JR, Tam A, Thiessen N, Varhol R, Zeng T, Zhao Y, Jones SJ, Marra MA, Saksena G, Cherniack AD, Schumacher SE, Tabak B, Carter SL, Pho NH, Nguyen H, Onofrio RC, Crenshaw A, Ardlie K, Beroukhim R, Winckler W, Hammerman PS, Getz G, Meyerson M, Protopopov A, Zhang J, Hadjipanayis A, Lee S, Xi R, Yang L, Ren X, Zhang H, Shukla S, Chen PC, Haseley P, Lee E, Chin L, Park PJ, Kucherlapati R, Socci ND, Liang Y, Schultz N, Borsu L, Lash AE, Viale A, Sander C, Ladanyi M, Auman T, Hoadley KA, Wilkerson MD, Shi Y, Liquori C, Meng S, Li L, Turman YJ, Topal MD, Tan D, Waring S, Buda E, Walsh J, Jones CD, Mieczkowski PA, Singh D, Wu J, Gulabani A, Dolina P, Bodenheimer T, Hoyle AP, Simons JV, Soloway MG, Mose LE, Jefferys SR, Balu S, O'Connor BD, Prins JF, Liu J, Chiang DY, Hayes D, Perou CM, Cope L, Danilova L, Weisenberger DJ, Maglinte DT, Pan F, Van Den Berg DJ, Triche T Jr, Herman JG, Baylin SB, Laird PW, Getz G, Noble M, Voet D, Saksena G, Gehlenborg N, DiCara D, Zhang J, Zhang H, Wu CJ, Liu SY, Lawrence MS, Zou L, Sivachenko A, Lin P, Stojanov P, Jing R, Cho J, Nazaire MD, Robinson J, Thorvaldsdottir H, Mesirov J, Park PJ, Chin L, Schultz N, Sinha R, Ciriello G, Cerami E, Gross B, Jacobsen A, Gao J, Aksoy B, Weinhold N, Ramirez R, Taylor BS, Antipin Y, Reva B, Shen R, Mo Q, Seshan V, Paik PK, Ladanyi M, Sander C, Akbani R, Zhang N, Broom BM, Casasent T, Unruh A, Wakefield C, Cason R, Baggerly KA, Weinstein JN, Haussler D, Benz CC, Stuart JM, Zhu J, Szeto C, Scott GK, Yau C, Ng S, Goldstein T, Waltman P, Sokolov A, Ellrott K, Collisson EA, Zerbino D, Wilks C, Ma S, Craft B, Wilkerson MD, Auman J, Hoadley KA, Du Y, Cabanski C, Walter V, Singh D, Wu J, Gulabani A, Bodenheimer T, Hoyle AP, Simons JV, Soloway MG, Mose LE, Jefferys SR, Balu S, Marron J, Liu Y, Wang K, Liu J, Prins JF, Hayes D, Perou CM, Creighton CJ, Zhang Y, Travis WD, Rekhtman N, Yi J, Aubry MC, Cheney R, Dacic S, Flieder D, Funkhouser W, Illei P, Myers J, Tsao MS, Penny R, Mallery D, Shelton T, Hatfield M, Morris S, Yena P, Shelton C, Sherman M, Paulauskis J, Meyerson M, Baylin SB, Govindan R, Akbani R, Azodo I, Beer D, Bose R, Byers LA, Carbone D, Chang LW, Chiang D, Chu A, Chun E, Collisson E, Cope L, Creighton CJ, Danilova L, Ding L, Getz G, Hammerman PS, Hayes D, Hernandez B, Herman JG, Heymach J, Ida C, Imielinski M, Johnson B, Jurisica I, Kaufman J, Kosari F, Kucherlapati R, Kwiatkowski D, Ladanyi M, Lawrence MS, Maher CA, Mungall A, Ng S, Pao W, Peifer M, Penny R, Robertson G, Rusch V, Sander C, Schultz N, Shen R, Siegfried J, Sinha R, Sivachenko A, Sougnez C, Stoll D, Stuart J, Thomas RK, Tomaszek S, Tsao MS, Travis WD, Vaske C, Weinstein JN, Weisenberger D, Wheeler D, Wigle DA, Wilkerson MD, Wilks C, Yang P, Zhang JJ, Jensen MA, Sfeir R, Kahn AB, Chu AL, Kothiyal P, Wang Z, Snyder EE, Pontius J, Pihl TD, Ayala B, Backus M, Walton J, Baboud J, Berton DL, Nicholls MC, Srinivasan D, Raman R, Girshik S, Kigonya PA, Alonso S, Sanbhadti RN, Barletta SP, Greene JM, Pot DA, Tsao MS, Bandarchi-Chamkhaleh B, Boyd J, Weaver J, Wigle DA, Azodo IA, Tomaszek SC, Aubry MC, Ida CM, Yang P, Kosari F, Brock MV, Rodgers K, Rutledge M, Brown T, Lee B, Shin J, Trusty D, Dhir R, Siegfried JM, Potapova O, Fedosenko KV, Nemirovich-Danchenko E, Rusch V, Zakowski M, Iacocca MV, Brown J, Rabeno B, Czerwinski C, Petrelli N, Fan Z, Todaro N, Eckman J, Myers J, Rathmell W, Thorne LB, Huang M, Boice L, Hill A, Penny R, Mallery D, Curley E, Shelton C, Yena P, Morrison C, Gaudioso C, Bartlett JM, Kodeeswaran S, Zanke B, Sekhon H, David K, Juhl H, Van Le X, Kohl B, Thorp R, Nguyen VT, Nguyen VB, Sussman H, Phu BD, Hajek R, Nguyen PH, Khan KZ, Muley T, Shaw KR, Sheth M, Yang L, Buetow K, Davidsen T, Demchok JA, Eley G, Ferguson M, Dillon LA, Schaefer C, Guyer MS, Ozenberger BA, Palchik JD, Peterson J, Sofia HJ, Thomson E.
Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.
PMID 22960745
 
Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis.
Horak P, Crawford AR, Vadysirisack DD, Nash ZM, DeYoung MP, Sgroi D, Ellisen LW.
Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4675-80. doi: 10.1073/pnas.0907705107. Epub 2010 Feb 22.
PMID 20176937
 
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr.
Science. 2001 Apr 20;292(5516):464-8. Epub 2001 Apr 5.
PMID 11292862
 
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ.
Science. 2001 Apr 20;292(5516):468-72. Epub 2001 Apr 5.
PMID 11292861
 
Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway.
Jin HO, An S, Lee HC, Woo SH, Seo SK, Choe TB, Yoo DH, Lee SB, Um HD, Lee SJ, Park MJ, Kim JI, Hong SI, Rhee CH, Park IC.
Cell Signal. 2007 Jul;19(7):1393-403. Epub 2007 Jan 20.
PMID 17307335
 
TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1.
Jin HO, Seo SK, Kim YS, Woo SH, Lee KH, Yi JY, Lee SJ, Choe TB, Lee JH, An S, Hong SI, Park IC.
Oncogene. 2011 Sep 1;30(35):3792-801. doi: 10.1038/onc.2011.102. Epub 2011 Apr 4.
PMID 21460850
 
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW.
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5.
PMID 10973499
 
REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase.
Katiyar S, Liu E, Knutzen CA, Lang ES, Lombardo CR, Sankar S, Toth JI, Petroski MD, Ronai Z, Chiang GG.
EMBO Rep. 2009 Aug;10(8):866-72. doi: 10.1038/embor.2009.93. Epub 2009 Jun 26.
PMID 19557001
 
Systematic and quantitative assessment of the ubiquitin-modified proteome.
Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ, Harper JW, Gygi SP.
Mol Cell. 2011 Oct 21;44(2):325-40. doi: 10.1016/j.molcel.2011.08.025. Epub 2011 Sep 8.
PMID 21906983
 
Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis.
Kimball SR, Do AN, Kutzler L, Cavener DR, Jefferson LS.
J Biol Chem. 2008 Feb 8;283(6):3465-75. Epub 2007 Dec 10.
PMID 18070882
 
Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.
Kucejova B, Pena-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander S, Wolff NC, Lotan Y, Xie XJ, Kabbani W, Kapur P, Brugarolas J.
Mol Cancer Res. 2011 Sep;9(9):1255-65. doi: 10.1158/1541-7786.MCR-11-0302. Epub 2011 Jul 28.
PMID 21798997
 
Ubiquitin ligase substrate identification through quantitative proteomics at both the protein and peptide levels.
Lee KA, Hammerle LP, Andrews PS, Stokes MP, Mustelin T, Silva JC, Black RA, Doedens JR.
J Biol Chem. 2011 Dec 2;286(48):41530-8. doi: 10.1074/jbc.M111.248856. Epub 2011 Oct 10.
PMID 21987572
 
Induction of a cell stress response gene RTP801 by DNA damaging agent methyl methanesulfonate through CCAAT/enhancer binding protein.
Lin L, Qian Y, Shi X, Chen Y.
Biochemistry. 2005a Mar 15;44(10):3909-14.
PMID 15751966
 
Arsenite induces a cell stress-response gene, RTP801, through reactive oxygen species and transcription factors Elk-1 and CCAAT/enhancer-binding protein.
Lin L, Stringfield TM, Shi X, Chen Y.
Biochem J. 2005b Nov 15;392(Pt 1):93-102.
PMID 16008523
 
RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation.
Malagelada C, Jin ZH, Greene LA.
J Neurosci. 2008 Dec 31;28(53):14363-71. doi: 10.1523/JNEUROSCI.3928-08.2008.
PMID 19118169
 
Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation.
Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ.
EMBO J. 2001 Sep 17;20(18):5197-206.
PMID 11566883
 
Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor.
Mata MA, Satterly N, Versteeg GA, Frantz D, Wei S, Williams N, Schmolke M, Pena-Llopis S, Brugarolas J, Forst CV, White MA, Garcia-Sastre A, Roth MG, Fontoura BM.
Nat Chem Biol. 2011 Sep 11;7(10):712-9. doi: 10.1038/nchembio.645.
PMID 21909097
 
Quantitative analysis of global ubiquitination in HeLa cells by mass spectrometry.
Meierhofer D, Wang X, Huang L, Kaiser P.
J Proteome Res. 2008 Oct;7(10):4566-76. doi: 10.1021/pr800468j. Epub 2008 Sep 10.
PMID 18781797
 
Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes.
Molitoris JK, McColl KS, Swerdlow S, Matsuyama M, Lam M, Finkel TH, Matsuyama S, Distelhorst CW.
J Biol Chem. 2011 Aug 26;286(34):30181-9. doi: 10.1074/jbc.M111.245423. Epub 2011 Jul 6.
PMID 21733849
 
Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG.
Nat Cell Biol. 2000 Jul;2(7):423-7.
PMID 10878807
 
The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila.
Reiling JH, Hafen E.
Genes Dev. 2004 Dec 1;18(23):2879-92. Epub 2004 Nov 15.
PMID 15545626
 
Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1.
Semenza GL.
Exp Physiol. 2006 Sep;91(5):803-6. Epub 2006 Jun 1.
PMID 16740642
 
A data set of human endogenous protein ubiquitination sites.
Shi Y, Chan DW, Jung SY, Malovannaya A, Wang Y, Qin J.
Mol Cell Proteomics. 2011 May;10(5):M110.002089. doi: 10.1074/mcp.M110.002089. Epub 2010 Oct 24.
PMID 20972266
 
Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis.
Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, Kalinski H, Kamer I, Rozen A, Mor O, Keshet E, Leshkowitz D, Einat P, Skaliter R, Feinstein E.
Mol Cell Biol. 2002 Apr;22(7):2283-93.
PMID 11884613
 
Regulation of mTOR and cell growth in response to energy stress by REDD1.
Sofer A, Lei K, Johannessen CM, Ellisen LW.
Mol Cell Biol. 2005 Jul;25(14):5834-45.
PMID 15988001
 
Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K, Makino Y, Pereira T, Poellinger L.
EMBO J. 2000 Aug 15;19(16):4298-309.
PMID 10944113
 
Structural analysis and functional implications of the negative mTORC1 regulator REDD1.
Vega-Rubin-de-Celis S, Abdallah Z, Kinch L, Grishin NV, Brugarolas J, Zhang X.
Biochemistry. 2010 Mar 23;49(11):2491-501. doi: 10.1021/bi902135e.
PMID 20166753
 
A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles.
Wagner SA, Beli P, Weinert BT, Nielsen ML, Cox J, Mann M, Choudhary C.
Mol Cell Proteomics. 2011 Oct;10(10):M111.013284. doi: 10.1074/mcp.M111.013284. Epub 2011 Sep 1.
PMID 21890473
 
Dexamethasone-induced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals.
Wang Z, Malone MH, Thomenius MJ, Zhong F, Xu F, Distelhorst CW.
J Biol Chem. 2003 Jul 18;278(29):27053-8. Epub 2003 May 7.
PMID 12736248
 
ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression.
Whitney ML, Jefferson LS, Kimball SR.
Biochem Biophys Res Commun. 2009 Feb 6;379(2):451-5. doi: 10.1016/j.bbrc.2008.12.079. Epub 2008 Dec 27.
PMID 19114033
 
Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia.
Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W, Brugarolas J.
Mol Cell Biol. 2011 May;31(9):1870-84. doi: 10.1128/MCB.01393-10. Epub 2011 Mar 7.
PMID 21383064
 
Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling.
Xu G, Paige JS, Jaffrey SR.
Nat Biotechnol. 2010 Aug;28(8):868-73. doi: 10.1038/nbt.1654. Epub 2010 Jul 18.
PMID 20639865
 
Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema.
Yoshida T, Mett I, Bhunia AK, Bowman J, Perez M, Zhang L, Gandjeva A, Zhen L, Chukwueke U, Mao T, Richter A, Brown E, Ashush H, Notkin N, Gelfand A, Thimmulappa RK, Rangasamy T, Sussan T, Cosgrove G, Mouded M, Shapiro SD, Petrache I, Biswal S, Feinstein E, Tuder RM.
Nat Med. 2010 Jul;16(7):767-73. doi: 10.1038/nm.2157. Epub 2010 May 16.
PMID 20473305
 
HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation.
Yu F, White SB, Zhao Q, Lee FS.
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9630-5.
PMID 11504942
 
Nuclear factor of activated T-cell c3 inhibition of mammalian target of rapamycin signaling through induction of regulated in development and DNA damage response 1 in human intestinal cells.
Zhou Y, Wang Q, Guo Z, Weiss HL, Evers BM.
Mol Biol Cell. 2012 Aug;23(15):2963-72. doi: 10.1091/mbc.E12-01-0037. Epub 2012 Jun 13.
PMID 22696685
 

Citation

This paper should be referenced as such :
Vega-Rubin-de-Celis, S ; Brugarolas, J
DDIT4 (DNA-damage-inducible transcript 4)
Atlas Genet Cytogenet Oncol Haematol. 2013;17(6):404-410.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/DDIT4ID45802ch10q22.html


External links

Nomenclature
HGNC (Hugo)DDIT4   24944
Cards
AtlasDDIT4ID45802ch10q22
Entrez_Gene (NCBI)DDIT4  54541  DNA damage inducible transcript 4
AliasesDig2; REDD-1; REDD1
GeneCards (Weizmann)DDIT4
Ensembl hg19 (Hinxton)ENSG00000168209 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000168209 [Gene_View]  chr10:72273919-72276036 [Contig_View]  DDIT4 [Vega]
ICGC DataPortalENSG00000168209
TCGA cBioPortalDDIT4
AceView (NCBI)DDIT4
Genatlas (Paris)DDIT4
WikiGenes54541
SOURCE (Princeton)DDIT4
Genetics Home Reference (NIH)DDIT4
Genomic and cartography
GoldenPath hg38 (UCSC)DDIT4  -     chr10:72273919-72276036 +  10q22.1   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)DDIT4  -     10q22.1   [Description]    (hg19-Feb_2009)
EnsemblDDIT4 - 10q22.1 [CytoView hg19]  DDIT4 - 10q22.1 [CytoView hg38]
Mapping of homologs : NCBIDDIT4 [Mapview hg19]  DDIT4 [Mapview hg38]
OMIM607729   
Gene and transcription
Genbank (Entrez)AF335324 AK000507 AL136668 AM392607 AY090097
RefSeq transcript (Entrez)NM_019058
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)DDIT4
Cluster EST : UnigeneHs.744875 [ NCBI ]
CGAP (NCI)Hs.744875
Alternative Splicing GalleryENSG00000168209
Gene ExpressionDDIT4 [ NCBI-GEO ]   DDIT4 [ EBI - ARRAY_EXPRESS ]   DDIT4 [ SEEK ]   DDIT4 [ MEM ]
Gene Expression Viewer (FireBrowse)DDIT4 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevestigatorExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)54541
GTEX Portal (Tissue expression)DDIT4
Human Protein AtlasENSG00000168209-DDIT4 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9NX09   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ9NX09  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ9NX09
Splice isoforms : SwissVarQ9NX09
PhosPhoSitePlusQ9NX09
Domains : Interpro (EBI)RTP801-like   
Domain families : Pfam (Sanger)RTP801_C (PF07809)   
Domain families : Pfam (NCBI)pfam07809   
Conserved Domain (NCBI)DDIT4
DMDM Disease mutations54541
Blocks (Seattle)DDIT4
PDB (SRS)3LQ9   
PDB (PDBSum)3LQ9   
PDB (IMB)3LQ9   
PDB (RSDB)3LQ9   
Structural Biology KnowledgeBase3LQ9   
SCOP (Structural Classification of Proteins)3LQ9   
CATH (Classification of proteins structures)3LQ9   
SuperfamilyQ9NX09
Human Protein Atlas [tissue]ENSG00000168209-DDIT4 [tissue]
Peptide AtlasQ9NX09
HPRD09662
IPIIPI00550489   
Protein Interaction databases
DIP (DOE-UCLA)Q9NX09
IntAct (EBI)Q9NX09
FunCoupENSG00000168209
BioGRIDDDIT4
STRING (EMBL)DDIT4
ZODIACDDIT4
Ontologies - Pathways
QuickGOQ9NX09
Ontology : AmiGOresponse to hypoxia  neuron migration  intracellular  cytoplasm  mitochondrion  cytosol  cytosol  brain development  cell proliferation  negative regulation of peptidyl-threonine phosphorylation  neuron differentiation  negative regulation of TOR signaling  negative regulation of peptidyl-serine phosphorylation  intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator  protein complex disassembly  negative regulation of glycolytic process  neurotrophin TRK receptor signaling pathway  defense response to virus  cellular response to dexamethasone stimulus  14-3-3 protein binding  reactive oxygen species metabolic process  positive regulation of neuron death  negative regulation of intracellular signal transduction  
Ontology : EGO-EBIresponse to hypoxia  neuron migration  intracellular  cytoplasm  mitochondrion  cytosol  cytosol  brain development  cell proliferation  negative regulation of peptidyl-threonine phosphorylation  neuron differentiation  negative regulation of TOR signaling  negative regulation of peptidyl-serine phosphorylation  intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator  protein complex disassembly  negative regulation of glycolytic process  neurotrophin TRK receptor signaling pathway  defense response to virus  cellular response to dexamethasone stimulus  14-3-3 protein binding  reactive oxygen species metabolic process  positive regulation of neuron death  negative regulation of intracellular signal transduction  
Pathways : KEGGmTOR signaling pathway    PI3K-Akt signaling pathway    MicroRNAs in cancer   
REACTOMEQ9NX09 [protein]
REACTOME PathwaysR-HSA-5628897 [pathway]   
NDEx NetworkDDIT4
Atlas of Cancer Signalling NetworkDDIT4
Wikipedia pathwaysDDIT4
Orthology - Evolution
OrthoDB54541
GeneTree (enSembl)ENSG00000168209
Phylogenetic Trees/Animal Genes : TreeFamDDIT4
HOVERGENQ9NX09
HOGENOMQ9NX09
Homologs : HomoloGeneDDIT4
Homology/Alignments : Family Browser (UCSC)DDIT4
Gene fusions - Rearrangements
Tumor Fusion PortalDDIT4
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerDDIT4 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)DDIT4
dbVarDDIT4
ClinVarDDIT4
1000_GenomesDDIT4 
Exome Variant ServerDDIT4
ExAC (Exome Aggregation Consortium)ENSG00000168209
GNOMAD BrowserENSG00000168209
Genetic variants : HAPMAP54541
Genomic Variants (DGV)DDIT4 [DGVbeta]
DECIPHERDDIT4 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisDDIT4 
Mutations
ICGC Data PortalDDIT4 
TCGA Data PortalDDIT4 
Broad Tumor PortalDDIT4
OASIS PortalDDIT4 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICDDIT4  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDDDIT4
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch DDIT4
DgiDB (Drug Gene Interaction Database)DDIT4
DoCM (Curated mutations)DDIT4 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)DDIT4 (select a term)
intoGenDDIT4
NCG5 (London)DDIT4
Cancer3DDDIT4(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM607729   
Orphanet
DisGeNETDDIT4
MedgenDDIT4
Genetic Testing Registry DDIT4
NextProtQ9NX09 [Medical]
TSGene54541
GENETestsDDIT4
Target ValidationDDIT4
Huge Navigator DDIT4 [HugePedia]
snp3D : Map Gene to Disease54541
BioCentury BCIQDDIT4
ClinGenDDIT4
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD54541
Chemical/Pharm GKB GenePA134977994
Clinical trialDDIT4
Miscellaneous
canSAR (ICR)DDIT4 (select the gene name)
Probes
Litterature
PubMed65 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineDDIT4
EVEXDDIT4
GoPubMedDDIT4
iHOPDDIT4
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Nov 21 14:48:14 CET 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.